Medication and Grief: When Antidepressants Help (and When They Don't)

Normal grief — what clinicians call uncomplicated bereavement — is not a mental disorder. After a significant loss, waves of sadness, crying, disrupted sleep, difficulty concentrating, and even brief thoughts of wanting to be with the deceased are expected and appropriate. These experiences are painful, but they are not pathological. They follow a course, they respond to the natural passage of time and the support of community, and they do not require medical intervention.

Prolonged grief disorder (PGD) — added to DSM-5-TR in 2022 and previously known as complicated grief — is something different. PGD is characterized by:

• Intense yearning or longing for the deceased that persists beyond 12 months after the death (6 months for children)
• Preoccupation with the deceased or the circumstances of death that is pervasive and disabling
• Significant functional impairment — inability to maintain work, relationships, or daily activities
• At least 3 of 8 additional symptoms: identity disruption, disbelief about the death, avoidance of reminders, intense emotional pain, difficulty engaging in life, emotional numbness, feeling that life is meaningless, intense loneliness

The 12-month threshold is clinically significant. Many people experience profound grief for 6–12 months that is still within the expected range of bereavement. PGD is specifically the subset of grief that does not follow the normal trajectory — that remains locked in acute intensity long after most bereaved individuals have begun, with appropriate support, to integrate their loss.

The inclusion of bereavement-related exclusions in prior versions of the DSM — and their subsequent removal in DSM-5 — generated significant controversy. Jerome Wakefield's work on what he called “the medicalization of sadness” argued that removing the bereavement exclusion from major depression criteria risks pathologizing a normal, adaptive human response to one of life's most significant losses.

This is a legitimate concern. Grief involves suffering — genuine, profound suffering — but suffering is not the same as disorder. The DSM-5 authors acknowledged this tension: the removal of the bereavement exclusion was not a statement that grief equals depression, but a recognition that severe grief and MDD can coexist and that grief does not protect against depression.

The clinical and ethical imperative is to resist the impulse to prescribe medication simply to quiet grief. Grief is a human process that, when allowed to unfold with adequate support, has its own integrity and meaning. Medication prescribed to abbreviate that process is not only potentially unhelpful — it may interfere with the emotional work that healthy grieving requires.

Grief and major depressive disorder can coexist, and grief can precipitate a true depressive episode in vulnerable individuals. The symptom overlap is real and can make differentiation clinically difficult. Several features suggest that what is happening has crossed into MDD and warrants the same clinical attention as a depressive episode occurring at any other time:

• Suicidal ideation with intent or plan — while passive thoughts of wanting to be with the deceased are common in uncomplicated grief, active suicidal ideation with a plan, or thoughts of ending one's life for reasons beyond reunion with the deceased, require immediate clinical attention
• Psychomotor retardation — observable slowing of speech, movement, and thinking that is pronounced and persistent, not episodic sadness
• Inability to function at baseline — not temporarily disrupted functioning, but inability to maintain basic self-care, employment, or parenting for an extended period
• Profound worthlessness and self-blame — grief typically produces guilt about specific things (things left unsaid, time not spent); MDD produces pervasive worthlessness unrelated to the loss
• Symptoms persisting beyond 2 months at MDD diagnostic criteria intensity

When these features are present, treating the overlapping depressive episode — including with medication when indicated — is clinically appropriate. The goal is not to eliminate grief; it is to treat the depression that is occurring alongside it.

PGD's addition to DSM-5-TR opened the door to studying it as a distinct target for treatment — both therapeutic and, potentially, pharmacological. As of now, there is no FDA-approved medication specifically for prolonged grief disorder. The research is evolving, and early studies have examined SSRIs, particularly citalopram and escitalopram, in PGD populations with mixed results.

What the evidence does show: the yearning, longing, and intrusive preoccupation central to PGD respond differently to antidepressants than the neurovegetative symptoms of MDD. Medication may reduce comorbid anxiety or depressive symptoms in PGD, but it does not appear to directly address the grief-specific phenomenology — the yearning itself, the sense of disrupted identity, the inability to accept the reality of the loss. This is why therapy is so central to PGD treatment.

Complicated grief therapy (CGT), developed by Katherine Shear and colleagues at Columbia University, is the evidence-based first-line treatment for PGD. It is a specialized form of psychotherapy that integrates elements of cognitive-behavioral therapy, interpersonal therapy, and motivational interviewing — designed specifically for the phenomenology of prolonged grief.

CGT works through two parallel processes:

• Loss processing — revisiting the story of the loss, tolerating grief emotions, addressing aspects of the death that are particularly difficult to accept, and working with memories of the deceased in a way that allows the relationship to be transformed rather than ended
• Restoration focus — identifying what the bereaved person wants from their life going forward, what the deceased would have wanted for them, and taking steps toward rebuilding an identity and future that incorporates but is not imprisoned by the loss

In randomized controlled trials, CGT significantly outperforms standard interpersonal therapy for PGD — and outperforms medication alone. When medication is used in PGD, it is typically adjunctive to CGT, not a substitute for it.

Medication is not a grief eraser. It will not shorten the duration of normal grief, accelerate acceptance, or eliminate the pain of loss. Prescribers who frame antidepressants this way are misrepresenting the evidence and setting patients up for disappointment and potentially for interference with the grief process.

What medication can do:

• Treat comorbid MDD — when grief has precipitated a full depressive episode, SSRIs and SNRIs can address the neurovegetative symptoms (sleep, energy, concentration, psychomotor slowing) that are making it impossible to engage with grief therapeutically
• Address sleep dysregulation — disrupted sleep is nearly universal in acute grief and significantly impairs resilience and coping capacity. Low-dose tricyclics (doxepin, nortriptyline), mirtazapine, or trazodone can address sleep-specific symptoms without the dependency risks of benzodiazepines
• Manage anxiety — grief is frequently accompanied by significant anxiety, which can respond to SSRIs or buspirone without the risks associated with benzodiazepines in this population
• Reduce the floor — in patients where grief has produced a level of neurobiological dysregulation that makes engagement in therapy impossible, medication can stabilize enough to allow the therapeutic work to begin

The evidence for antidepressants in grief is more modest than for depression generally — and more specific. The clearest data:

• When bereaved individuals meet full MDD criteria, antidepressants are as effective as they are in non-bereaved MDD populations — and the evidence supports using them
• For PGD specifically, antidepressants reduce comorbid depressive and anxiety symptoms but show limited direct effect on the grief-specific symptoms (yearning, intrusive grief, disrupted sense of meaning)
• A randomized trial by Shear and colleagues found that adding citalopram to CGT did not improve PGD outcomes beyond CGT alone — suggesting that for PGD without comorbid MDD, therapy is the primary intervention

The honest clinical summary: antidepressants have a real but limited role in grief. When MDD criteria are met, they are appropriate. When the picture is uncomplicated grief or PGD without comorbid MDD, the evidence tilts strongly toward therapy as the primary intervention with medication as adjunct for specific symptom targets.

Benzodiazepines (lorazepam, clonazepam, alprazolam, diazepam) are sometimes prescribed in acute grief for anxiety and sleep — and while there is a short-term rationale, many experienced prescribers approach this cautiously or avoid it entirely.

The concerns:

• Dependency risk — benzodiazepines are physically addictive. In a population that is already psychologically vulnerable and at elevated substance use risk, prescribing a dependency-forming agent requires careful consideration
• Grief process interference — there is clinical concern (though limited RCT evidence) that benzodiazepine-induced emotional blunting may interfere with the emotional processing that healthy grieving requires
• Tolerance development — the anxiolytic effects diminish with continued use while physical dependence develops, often requiring a careful taper to discontinue

If benzodiazepines are used, it is typically for a very brief, clearly time-limited course (days to 1–2 weeks maximum) for severe acute anxiety or sleep disruption, with a clear plan for transition to non-benzodiazepine alternatives. Many clinicians prefer to reach for safer sleep and anxiety options first.

Grief expression and the meaning-making that follows loss are profoundly shaped by cultural and spiritual context. What looks like prolonged grief to a Western clinician may be entirely normative in a cultural tradition that emphasizes extended mourning. What appears as social withdrawal may be a culturally prescribed mourning practice.

Clinically significant considerations:

• Many cultures have mourning rituals, timelines, and expectations that differ significantly from the implicit norms embedded in Western psychiatric criteria
• Spiritual frameworks — including beliefs about the afterlife, the ongoing presence of the deceased, and the meaning of death — can be profound resources in grief, but they can also be sources of guilt or unresolved conflict that complicate healing
• Help-seeking for grief is more stigmatized in some communities, and the framing of grief as a “medical problem” requiring “medication” can itself be a barrier to engagement
• A culturally humble clinical encounter asks: what does grief look like in your community? What have you found helpful? What would your family think about seeking professional help?

Many people struggle to articulate their grief to a prescriber, especially in a short appointment. Here are specific scripts for the conversation:

If You Think You May Have MDD on Top of Grief

• “I lost [person] [timeframe] ago, and since then I've been struggling to function. I'm not just sad — I feel numb, I can't sleep, I can't concentrate at work, and I've had some thoughts that scare me. I want to understand whether what I'm experiencing is grief or something that needs treatment.”
• “My grief has started to look less like sadness about my loss and more like an inability to function — I'm not eating, not leaving the house, and feeling worthless in ways that feel different from just missing them.”

If You Are Struggling With Sleep During Grief

• “I'm not looking for something to take away my grief — but I haven't slept properly in [timeframe], and I think that's making everything worse. Can we talk about options that don't carry dependency risk?”

What to Bring to the Appointment

• When the loss occurred and who or what you lost
• Specific functional impairments (work, parenting, self-care) and how long they have been occurring
• Any symptoms that concern you most — sleep, thoughts of suicide, inability to eat
• What support you currently have — therapy, community, family
• Whether you want to understand your options vs. actively seeking medication (your prescriber should respect this distinction)